文献速递心境障碍焦虑、强迫与应激相关障碍

生酮饮食与抑郁和焦虑:系统综述与荟萃分析

Ketogenic Diets and Depression and Anxiety: A Systematic Review and Meta-Analysis.
PubMed 文献 · JAMA Psychiatry · 2026-01-01

10项RCT显示生酮饮食与抑郁症状改善显著相关(SMD=-0.48),但9项RCT未发现与焦虑症状的显著关联;准实验研究显示两者均有一致关联,但证据确定性有限。

要点

  • 生酮饮食与抑郁症状改善存在 modest 关联,尤其在监测酮体、非肥胖人群和极低碳水干预中更强。
  • 随机对照试验未发现生酮饮食与焦虑症状的显著关联,焦虑证据尚不确定。
  • 现有证据异质性高、对照饮食不一且随访短,需高质量试验确认疗效与持久性。

核心结论

  • 生酮饮食与抑郁症状的 modest 改善相关,尤其在生化酮症验证的研究中关联更强。
  • 焦虑症状的随机对照试验证据未显示显著关联,整体证据尚不确定。

研究设计与样本

  • 系统综述与荟萃分析,检索MEDLINE、Embase和APA PsycINFO(2025年4月18日),并手动检索和临床试验注册库。
  • 纳入成人(≥18岁)接受生酮饮食(碳水<26%能量或<50 g/天)并使用验证性精神科量表评估的研究。
  • 采用Joanna Briggs Institute工具评估偏倚风险,对RCT和准实验研究分别进行随机效应荟萃分析。

主要发现

  • 10项RCT比较生酮饮食与对照饮食对抑郁症状的影响,显示显著关联(SMD=-0.48;95% CI,-0.87至-0.10;I2=67.2%)。
  • 9项RCT评估焦虑症状,未显示显著关联(SMD=-0.03;95% CI,-0.18至0.12;I2=41%)。
  • 9项准实验研究显示生酮饮食与抑郁症状一致关联(SMCC=-0.66;95% CI,-0.83至-0.50;I2=0%)。
  • 6项准实验研究显示生酮饮食与焦虑症状类似关联(SMCC=-0.58;95% CI,-0.81至-0.36;I2=0%)。

关键数值与推荐

  • 生酮饮食定义:碳水化合物<26%能量或<50 g/天。
  • 抑郁症状RCT的合并SMD为-0.48(95% CI,-0.87至-0.10),I2=67.2%。
  • 焦虑症状RCT的合并SMD为-0.03(95% CI,-0.18至0.12),I2=41%。
  • 准实验研究抑郁症状SMCC为-0.66(95% CI,-0.83至-0.50),I2=0%;焦虑症状SMCC为-0.58(95% CI,-0.81至-0.36),I2=0%。

临床怎么用

  • 对于抑郁症状,生酮饮食可能作为辅助干预选项,但需在监测酮体和结构化支持下进行。
  • 焦虑症状暂不支持将生酮饮食作为有效干预,临床决策应基于现有证据局限性。
  • 需注意研究异质性高、对照饮食不一且随访短,不宜过度推广。

局限性

  • 研究间异质性较高(抑郁RCT I2=67.2%)。
  • 对照饮食类型不一,可能影响结果解释。
  • 随访时间短,长期疗效和持久性未知。
  • 需更大样本、标准化验证方案和预设结局的试验确认疗效。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Ketogenic diets (KDs) have been hypothesized to influence mental health through pathways involving mitochondrial function, inflammation, and neurotransmitters, but their therapeutic value in psychiatric populations remains uncertain. OBJECTIVE: To assess the associations between KDs and mental health outcomes in adults, with a focus on depressive and anxiety symptoms. DATA SOURCES: MEDLINE, Embase, and APA PsycINFO were searched on April 18, 2025. Additional studies were identified through manual searches and clinical trial registries. STUDY SELECTION: Studies involving adults aged 18 years or older receiving a KD (<26% energy from carbohydrates or <50 g/day) and assessed with validated psychiatric scales were eligible. Designs included randomized clinical trials (RCTs), quasi-experimental (QSE) studies, cross-sectional studies, case series, and case reports. DATA EXTRACTION AND SYNTHESIS: Data were extracted by 1 reviewer and verified by 2 others. Risk of bias was assessed using critical appraisal tools from the Joanna Briggs Institute. Random-effects meta-analyses were run separately for RCTs and QSEs. MAIN OUTCOMES AND MEASURES: The primary outcome was changes in psychiatric symptom severity measured by standardized scales, reported as standardized mean differences (SMDs) or standardized mean change using change scores (SMCCs). RESULTS: A total of 50 studies (41 718 participants) were included. Ten RCTs on KD for depressive symptoms vs control diets showed a significant association (SMD, -0.48; 95% CI, -0.87 to -0.10; I2 = 67.2%), with stronger associations in studies using ketone monitoring, nonobese participants, very low-carbohydrate interventions, and non-high-carbohydrate comparators. Nine RCTs on anxiety showed no significant association (SMD, -0.03; 95% CI, -0.18 to 0.12; I2 = 41%). In QSEs, 9 on depressive symptoms showed a consistent association (SMCC, -0.66; 95% CI, -0.83 to -0.50; I2 = 0%), and 6 on anxiety showed similar results (SMCC, -0.58; 95% CI, -0.81 to -0.36; I2 = 0%). CONCLUSIONS AND RELEVANCE: In this systematic review and meta-analysis, KDs were associated with modest improvements in depressive symptoms, particularly with biochemical ketosis verification, while anxiety evidence was inconclusive. Given heterogeneity, comparators, and short follow-up, well-powered trials with standardized, verified protocols, structured support, and prespecified outcomes are needed to confirm efficacy and durability.

来源:JAMA Psychiatry,查看原文。版权归原作者所有。

引用

  1. Janssen-Aguilar R, Vije T, Peera M, et al. Ketogenic Diets and Depression and Anxiety: A Systematic Review and Meta-Analysis. JAMA Psychiatry. 2026. PMID: 41191382. doi:10.1001/jamapsychiatry.2025.3261

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。